The utility of 0.5% apraclonidine in the diagnosis of Horner syndrome

Archives of Ophthalmology

Volumn 121, Issue 8, 2003, Pages 1201-1203

  Brown, Sandra M ^a   Aouchiche, Rachid ^a   Freedman, Kenn A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; APRACLONIDINE; BRIMONIDINE; COCAINE; HYDROXYAMPHETAMINE;

ADULT; ANISOCORIA; ARTICLE; CLINICAL ARTICLE; DIAGNOSTIC ACCURACY; DRUG COST; DRUG MECHANISM; FEMALE; HORNER SYNDROME; HUMAN; MALE; PRIORITY JOURNAL; PUPIL;

ADRENERGIC ALPHA-AGONISTS; ADULT; AGED; ANISOCORIA; CLONIDINE; DRUG EVALUATION; FEMALE; HORNER SYNDROME; HUMANS; MALE; MIDDLE AGED; OPHTHALMIC SOLUTIONS; PUPIL;

EID: 0043063858     PISSN: 00039950     EISSN: None     Source Type: Journal    
DOI: 10.1001/archopht.121.8.1201     Document Type: Article

References (5)

1. Morales J, Brown SM, Abdul-Rahim AS, Crosson CE. Ocular effects of apraclonidine in Horner syndrome. Arch Ophthalmol. 2000;118:951-954.
2. Miller PE, Rhaesa SL. Effects of topical administration of 0.5% apraclonidine on intraocular pressure, pupil size, and heart rate in clinically normal cats. Am J Vet Res. 1996;57:83-86.
3. Langham ME, Weinstein GW. Horner's syndrome: ocular supersensitivity to adrenergic amines. Arch Ophthalmol. 1967;78:462-469.
4. Korczyn AD. Adrenergic denervation supersensitivity. Adv Neurol. 1975;9:113-120.
5. Crosson CE, Heath AR, DeVries GW, Potter DE. Pharmacological evidence for heterogeneity of ocular alpha 2 adrenoceptors. Curr Eye Res. 1992; 11:963-970.